In this study, only a small population of patients had a history of receiving BRAF inhibitors prior to sample collection (n = 63); thus, this remains an important area for future research in exploring outcomes of patients with various BRAF alterations across tumor subtypes to determine if BRAF inhibitors can alter the natural history of the disease. The gene discussed is BRAF; the disease is neoplasm.